

REMARKS

The claims are rejected under 35 USC§112, second paragraph, for concluding with the phrase "and pharmaceutically acceptable salts and individual diastereomers thereof." This and similar expressions have been rewritten in the alternative form and in the singular.

Claim 24 is rejected under 35 USC§112, first paragraph, for lacking enablement. The claim has been canceled to expedite prosecution.


Claim 21, which claims specific examples, has been canceled and rewritten as new Claim 27, which includes the structures of the specific compounds in the examples.

All of the grounds for rejection have been overcome. The claims are in condition for allowance. Such allowance is earnestly solicited.

A fee is not believed to be required with this timely response. If any fee is required, the fee may be charged to Merck Deposit Account No. 13-2755.

If the examiner needs to discuss any matter relating to this application, the examiner is invited to telephone the undersigned attorney at the number below.

Respectfully submitted,

By   
James L. McGinnis  
Reg. No. 34,387  
Attorney for Applicant

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-0641

Date: April 11, 2008